ChemotherapyFDA-approvedFirst-line
Vincristine
How it works
Interferes with the microtubules in cancer cells, preventing cell division and leading to cell death.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 70% of patients achieved a complete remission, with a median overall survival of approximately 2 years.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Venetoclax and Vincristine in Relapsed Leukemia Patients | Leukemia | phase-1 | — | Source → |
| Measuring Vincristine in Cancer Cells | Leukemia | lab-study | — | Source → |
| New Chemotherapy Combination Tested in Children with Relapsed Leukemia | Leukemia | phase-1 | Complete remissions were seen in 87.5% of participants in Cohort A, 37.5% in Cohort B, and 20% in Cohort C. | Source → |
| Periwinkle Flower Compounds Used in Cancer Treatment | Leukemia | review | — | Source → |
| Vincristine-Steroid Pulses in Pediatric Leukemia Treatment | Leukemia | meta-analysis | Meta-analysis of event-free survival data suggested no benefit between more frequent or less frequent pulses (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.85-1.09). | Source → |
| Monitoring Vincristine in Cancer Patients for Better Treatment | Leukemia | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.